Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Senate panel narrowly tacks "pay-for-delay" ban onto a spending bill

This article was originally published in Scrip

Executive Summary

Drug makers may have been relieved by the US Senate's last-minute decision to drop several amendments from a war-funding bill that included a House provision banning "pay-for-delay" deals, but the issue has not died: on 29 July, a similar provision limiting generic drug makers' ability to accept money to settle patent disputes was cleared by the Senate Appropriations Committee.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts